Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

Type II cryoglobulinemic vasculitis in patients with Sjögren disease is associated with nearly a sevenfold increased risk for ...

Trump told CNBC he will initially impose a “small tariff” on pharmas in the next week or so, but will raise it to 150% in a ...

CureVac (CVAC) and GSK (GSK) to receive $740M and other payments in a settlement with Pfizer (PFE) and BioNTech (BNTX) over ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on ...

The tussle had centred on the development of mRNA jab technology, which was at the forefront of the fight against Covid-19.

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

UK pharma major GSK (LSE: GSK) today announced that, in connection with the mRNA patent settlement reached between CureVac ...

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...

GSK (GSK) announces that, in connection with the mRNA patent settlement reached between CureVac (CVAC) and BioNTech on 7 August 2025, the Company will receive an upfront settlement of $370M. GSK will ...